Table 1.

Subject characteristics.

	ST (n = 6) (disease duration <2 years)	LT (n = 7) (disease duration >10 years)	P
Disease duration (years)	0.79 ± 0.49	15.29 ± 5.53	0.003a
Age
Mean	25.7 ± 2.66	43.1 ± 9.16	0.008a
Median	25.5	45
Range	23–29	27–55
Sex
Female (%)	83	100
Male (%)	17	0
Ethnicity
African American (%)	17	57	0.242
Hispanic (%)	83	29	0.103
Caucasian (%)	0	14	0.462
Education (years)	12.83 ± 2.14	12.85 ± 3.02	0.942
SLEDAI	1.67 ± 1.5	2.0 ± 2.30	0.940
DI	0.17 ± 0.41	1.29 ± 1.25	0.048a
History of NPSLE	0	0
Anti-dsDNA titer (%)b	33	43	0.59
Anticardiolipin (%)c	33	29	0.72
Prednisoned	14.17 ± 14.71	4.11 ± 5.62	0.127
Cellcept(current)	67%	14%	0.063
Azathioprine(current)	0	14%	0.355
Cyclophosphamide(current)	17%	0	0.280
Current DMARDe	83%	29%	0.058
DMARD ever	83%	71%	0.626
Hypertensionf	50%	0	0.181
Diabetes mellitusg	0	14%	0.355

^aP < 0.05.

^bCurrent anti-dsDNA titer; percent positive.

^cAnticardiolipin antibody titer; percent positive IgG or IgM by history.

^dCurrent prednisone dose.

^eDMARD, disease-modifying antirheumatic drugs include cyclophosphamide, methotrexate, azathioprine or cellcept for >2 months.

^fCurrent hypertension requiring medication.

^gCurrent diabetes mellitus requiring medication.